Abbott to acquire rights to chronic pain treatment

ABBOTT PARK, Ill. Abbott is banking on a biotech drug in early-stage clinical trials to treat chronic pain, the drug company announced Thursday.

Abbott said it would acquire global rights to PanGenetics BV’s drug PG110, a monoclonal antibody that works by blocking nerve growth factor, which the body releases at sites of tissue damage and inflammation and plays a significant role in the transmission of pain signals through the nervous system. Abbott will pay PanGenetics $170 million upfront and milestone payments of up to $190 million.

“The goal for treatment of chronic pain continues to be potent, long-lasting analgesia that is tolerable for patients without the potential for dependence and abuse,” Abbott SVP global research and development John Leonard said in a statement. “NGF blockers have demonstrated the potential to address all of these needs, making them a promising treatment for chronic pain.”

Poll

Poll

Which of the current U.S. Presidential hopefuls do you think would be best for your business?

Hillary Clinton

Jeb Bush

Donald Trump

Ted Cruz

Ben Carson

Scott Walker

Marco Rubio

Rand Paul

Chris Christie

Mike Huckabee

SPECIAL REPORTS

Pharmacy’s battle for recognition continues

Fifty years ago this summer, President Lyndon B. Johnson secured his place in history by signing into law the legislation that created Medicare and Medicaid. To commemorate the anniversary, Drug Store News has put together an exclusive report on the effect that Medicare and Medicaid have had on the retail pharmacy industry and how it has transformed the role of the pharmacist. more...

IN THIS ISSUE

In this issue, DSN profiles Rite Aid and how the company is achieving a vision to become a retail healthcare company that delivers a higher level of care to its communities; takes you on a tour of Sears; offers insight into millennial shoppers and more. Click here to view the issue.